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Abstract
As some malaria control programs shift focus from disease control to transmission reduction, there is a need for
transmission data to monitor progress. At lower levels of transmission, it becomes increasingly more difficult to measure
precisely, for example through entomological studies. Many programs conduct regular cross sectional parasite prevalence
surveys, and have access to malaria treatment data routinely collected by ministries of health, often in health management
information systems. However, by themselves, these data are poor measures of transmission. In this paper, we propose an
approach for combining annual parasite incidence and treatment data with cross-sectional parasite prevalence and
treatment seeking survey data to estimate the incidence of new infections in the human population, also known as the
force of infection. The approach is based on extension of a reversible catalytic model. The accuracy of the estimates from
this model appears to be highly dependent on levels of detectability and treatment in the community, indicating the
importance of information on private sector treatment seeking and access to effective and appropriate treatment.
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Introduction
Much of the malarious world has seen substantial scale up in
intervention coverage in the last decade as a result of better
funding for national malaria control programs [1]. Some programs
are trying to reduce transmission with the long-term goal of
interrupting it [2], but there is no generally applicable approach
for measuring changes in transmission at low levels [3]. The
entomological inoculation rate (EIR), estimated as a product of the
sporozoite-positive host-seeking mosquitoes and the human-biting
rate, is a definitive measure of transmission, but its measurement is
technically challenging, labor intensive, provides only very
imprecise estimates with low external validity, and is not feasible
where EIR is low [4].
The incidence of new infections in the human population, also
known as the force of infection (FOI), is a measure of transmission
that is generally estimated without recourse to entomological
measurements. The method of clearing parasites with an effective
therapy and then following-up to observe when re-infection occurs
is well established as an approach for measuring FOI in
observational studies [5,6] and intervention trials [7–9]. An
alternative way of estimating FOI is by molecular typing of
sequential samples of blood from exposed individuals [10]. Both of
these methods require multiple field visits to a study cohort, and
thus neither is cost-effective nor feasible as a routine monitoring
approach. In low transmission settings, FOI can be estimated
using serological approaches, making use of simple differential
equation models to translate age-profiles of sero-positivity into a
history of exposure [11]. These approaches are being used to
compare transmission intensity across different settings [12,13],
but are of limited value in tracking rapid changes in transmission.
Longitudinal patterns of clinical incidence clearly provide most
of the accessible information with which to track such changes,
largely because of the relative abundance of annual parasite index
(API) data through routine health information systems. In fact, in
many parts of the world with low levels of transmission, especially
outside Africa, the only malariometric data routinely collected are
health facility-based clinical incidence (API) data. These data
provide no information about sub-clinical infections, home treated
infections, or infections among those not seeking treatment within
the health system and can not be used directly to estimate
transmission intensity.
In many settings, levels of malaria endemicity are assessed using
parasite prevalence derived from population-based household
surveys. In most infectious diseases, transmission can be measured
by the incidence of infection, which can be estimated as prevalence
divided by the average duration of infection. For malaria,
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however, the same prevalence value can result from a wide range
of EIR values [3], depending on biting densities of mosquitoes,
variations in how long infections persist, and the frequency of
treatment within the community. Box S1 describes common
metrics used to measure malaria transmission. Further, duration of
malaria infections is hard to measure, and depends strongly on
treatment rates. As transmission is reduced, the sample size needed
to accurately estimate parasite prevalence (or changes in
prevalence) using household surveys increases, making it a poor
way to measure endemicity or transmission [14].
In this paper we propose an approach using a combination of
API and prevalence survey data to estimate FOI. The approach is
based on extending a reversible catalytic model [15] previously
used for modeling the infection and recovery process for
Plasmodium falciparum malaria [16,17]. The extension allows for 1)
the effect of treatment on duration of infection and 2) the
incorporation of imperfect detection of infections in sampled
individuals, or detectability [18]. The effect of treatment, through
impact on the duration of infection, alters the relationship between
incidence and prevalence. Detectability is most likely to be
imperfect among individuals with asymptomatic infections
[18,19]. The extensions proposed here incorporate this bias in
prevalence estimates, while remaining accessible and computable
without the need for sophisticated software.
Model
We use a reversible catalytic model of the relationship between
prevalence and the force of infection, developed by Muench [15]
and later adapted to malaria by Bekessy [16], which assumes that
infections are distributed randomly over the population. The
general form of the model is
dP
dt
~l 1{Pð Þ{mP, ð1Þ
where P is (blood stage) parasite prevalence, l is FOI or incidence
of new infections per person per time unit, and m is the clearance
rate of an infection per person per time unit (equal to the
reciprocal of the average duration of an infection). Solving the
above equation for l at equilibrium (where dP=dt~0) yields
l~
mP
1{Pð Þ : ð2Þ
This approach assumes that the equilibrium parasite prevalence in
the population is a result of infection clearance and acquisition,
and assumes prefect detectability of infection. Under the
assumptions that having a pre-existing asymptomatic infection
does not change the probability of acquiring a symptomatic
infection, that only newly acquired infections can cause clinical
cases, and that a proportion a of these gets randomly, promptly,
appropriately and effectively treated, without contributing to the
parasite prevalence, the rate at which parasite negative individuals
become positive is l~ 1{að Þl0, with l0 the FOI in the absence of
treatment, corresponding to the rate at which infections are
introduced. Data of 311 malaria therapy patients show that the
first day of fever is 3 days (median) after the onset of detectable
parasitaemia, with 98.7% less than 10 days, out of an average
infection duration of about 200 days.
The average clearance rate m can be written m~m0zrx, with m0
the natural clearance rate and rx~al0 the (measurable) number of
(new) infections receiving treatment per person per time unit, i.e.
the treatment rate. Asymptomatic infections are thus naturally
cleared with rate m0, or when a new symptomatic super infection
occurs which gets treated (clearing also the asymptomatic
infection). This leads to:
dP
dt
~ 1{að Þl0 1{Pð Þ{ m0zal0ð ÞP~l0 1{Pð Þ{m0P{al0: ð3Þ
Again assuming equilibrium, this leads to an estimate of the FOI of
l0~
m0Pzrx
1{P
~
m0P
1{P{a
~
m0
1{a
P
{1
, ð4Þ
with information on treatment included, and m0 estimated from
the duration of untreated infections.
When detectability q, the probability of detecting an existing
infection (in a cross-sectional survey), is incorporated into the
model, an additional term Q, for the measured prevalence, is
required. True prevalence, P, is related to measured prevalence, Q,
by the relationship P~Q=q.
With P substituted, the model incorporating both treatment and
detectability in the equilibrium state is
l0~
m0
Q
q
zrx
1{
Q
q
~
m0Qzrxq
q{Q
~
m0Q
q 1{að Þ{Q~
m0
q
Q
1{að Þ{1
: ð5Þ
This model considers all parasites in an infected host as equivalent,
and all hosts as identical. Additionally, as this is an equilibrium
model, it does not account for seasonality or trends, but it can be
repeatedly estimated over time. Model parameters are summa-
rized in Box S2.
In the limit when prevalence is zero (Q~0) then the estimated
force of infection is equal to the rate of treatment l0~rx. Figure 1
illustrates the relationship between FOI (l0) and treatment rate at
5% and 25% measured prevalence and an average natural
parasitaemia duration of 200 days with perfect detectability and
50% detectability [18]. The difference in FOI at the two
detectability levels is small at 5% measured prevalence, and larger
at 25% measured prevalence. When detectability is at 50%, the
FOI estimate is higher due to infections which are missed in cross
sectional prevalence surveys. A higher treatment rate corresponds
to higher incidence for the same observed prevalence, in-line with
expectations.
Figure 2 shows the relationship between the measured
prevalence against FOI under two different assumptions about
treatment; 20% or 40% of new infections receiving curative
treatment. The curves have an asymptote at the measured
prevalence Q~q 1{að Þ. For example, at 50% detectability of
parasitaemia in cross sectional surveys and 20% of new infections
treated, the model has an asymptote at a measured prevalence of
40%, while with 40% of new infections treated, measured
prevalence is 30%. As expected, with 100% detectability, the
observed prevalence values are exactly double that of the values at
50% detectability. Near the asymptote, the ability to estimate the
FOI from the measured prevalence Q is limited.
Figure 3 shows the relationship between the FOI (l0) against the
probability of detecting an existing parasitaemic infection (in a
cross sectional survey) at two different measured prevalences; 5%
or 25%. The curves have asymptotes at q~Q= 1{að Þ near to
which the estimate of the FOI is very sensitive to the detectability.
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Model with Field Data
Data on treatment were derived from malaria epidemic
detection surveillance sentinel sites in Ethiopia [20–22]. All
sentinel sites have shown high (nearly perfect) testing rates among
suspect cases and good adherence of providers to test results.
Microscopy performance was variable across all sites, but in the
two selected sites, concordance with expert readings was high
(.90%). Over 1.5 years of observation at two sites, treatment rates
were estimated based on API data from the sentinel health centers
and treatment seeking behavior estimates from a malaria indicator
survey [20–22] (adjustments were made to increase the number of
treatments based on the fraction of patients who sought and
received anti-malarials in the private sector vs those who sought
care and received anti-malarials in the public sector). Estimates of
parasite prevalence from the malaria atlas project [21] were used
to estimate local parasite prevalence. Mean P. falciparum parasite
rates children from age 2 to age 10 (PfPR2–10) within a 10 km (2-
cell) radius of the health center were used as an estimate of local
malaria parasite prevalence. Tables 1 and 2 show the input values
for each site.
Yearly equilibrium FOI by month and averages across the
period for each Ethiopian sentinel site are shown in Figure 4.
This figure illustrates the sensitivity of measurement of FOI to
treatment rates and model specification in relation to detectability,
as the monthly estimates show that data from the dry period give
low estimates of annual FOI with perfect detectability and FOI
below 0.05 per person month assuming 50% detectability of
infections. Spikes in FOI were seen during transmission periods at
both sites, especially Bulbulla. Estimation of FOI with only data
from high transmission periods would lead to erroneously high
estimates of overall FOI for the entire period.
Discussion
Force of infection for P. falciparum malaria can be estimated by
combining API data and prevalence values from simple cross
sectional surveys, with an extension of Muench’s reversible
catalytic model. This provides a straightforward low-cost measure
Figure 1. Force of infection against treatment rate. Force of
infection (l0 : new infections per person year) against treatment rate
(new infections treated per person year) at 5% measured prevalence
(black lines) and 25% measured prevalence (blue lines), with perfect
detectability (solid lines) and 50% detectability (dotted lines), with an
average natural parasitaemia duration of 200 days.
doi:10.1371/journal.pone.0042861.g001
Figure 2. Measured prevalence against force of infection.
Measured prevalence against force of infection (l0 : new infections prior
to any treatment per person year) at 20% (red lines) and 40% (green
lines) treatment rate of new infections; perfect detectability (solid lines)
and 50% detectability (dotted lines), with an average natural
parasitaemia duration of 200 days.
doi:10.1371/journal.pone.0042861.g002
Figure 3. Force of infection against detectability of parasitae-
mia. Force of infection (l0 : new infections prior to any treatment per
person year) against the probability of detecting an existing
parasitaemic infection (in a cross sectional survey) at 5% measured
prevalence (solid lines) and 25% measured prevalence (dashed lines),
with a treatment probability of new infections of 20% (red lines) and
40% (green lines), with an average natural parasitaemia duration of 200
days.
doi:10.1371/journal.pone.0042861.g003
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of malaria transmission applicable in low transmission areas.
Catalytic models, which are much simpler than many other
malaria transmission models, have long been used for estimating
transmission rates from seroprevalence data [11,23,24]. They have
also previously been used to estimate EIR and FOI from
prevalence data obtained by microscopy [25]. However, these
studies either ignored treatment or did not distinguish effects of
treatment from those of natural infection clearance and imperfect
detectability. Treatment seeking, especially when efficacious anti-
malarials are available, dramatically affects any estimation of
transmission rates from infection data because effective treatment
substantially reduces the duration of infection [26,27]. Increas-
ingly, treatment is based on parasitological diagnosis using rapid
diagnostic tests (RDTs) and the number of treatments in health
facilities is being recorded in health management information
systems (HMISs). The use of RDTs has increased the value of
HMIS data, and in low transmission areas, API values derived
from HMISs are often used as measures of malaria transmission.
However, HMISs remain an unreliable and incomplete source
of treatment data [28] because they do not capture private sector
or home treatment for malaria, and need to be augmented by
population-based information on patients who seek treatment
outside the formal public sector. If HMIS data are to be used to
estimate transmission rates they also need to be augmented by
population-based parasite prevalence data, which provide infor-
mation on infections that have escaped treatment. Fortunately,
recalls of treatment-seeking behavior and parasite prevalence data
are both routinely collected in nationally representative malaria
indicator surveys (MISs) repeated every two to three years in many
endemic countries. The combination of MIS and HMIS data,
using the algorithm described in this paper, thus provides a widely
applicable means of estimating the FOI. One limitation of this
approach is that data on treatment seeking derived from nationally
representative surveys may fail to capture local variation.
Furthermore, such data, which are usually available only semi-
annually, will also fail to capture seasonal dynamics in treatment
seeking. In many areas, systems for collection of HMIS data are
weak and imprecise, and so would require strengthening before
they can be considered a reliable source of treatment data.
This approach involves several approximations. It relies on
equilibrium solutions, though in reality the system will generally
not be at equilibrium. The simple model described in the main
text also ignores the effects of super-infection, and does not
explicitly incorporate multiplicities of infection greater than one.
At high transmission levels, most hosts harbor many co-infecting
clones, but allowing for super-infection leads to substantially more
complicated models and requires an iterative approach for
estimating the FOI from prevalence and API data (see File S1).
Even these models with super-infection ignore further complica-
tions resulting from variations between hosts in levels of
detectability, acquired immunity, levels of exposure and in access
to treatment, all of which arise because of dependence between
infections and which are therefore important at higher levels of
transmission. At high incidences the same prevalence can thus
result from a wide range of EIR values [29], depending on these
sources of heterogeneity [30]. Where prevalence is above about
20%, a more detailed model capturing these effects would seem
appropriate. Further work should include analyses of sensitivity to
the assumptions about diagnostic performance, and more critical
evaluation of the limits over which the approach is applicable.
At lower prevalence, allowing for super-infection makes little
difference to the relationship of prevalence and FOI (see File S1
and Figures S1 and S2) and it appears as if it is reasonable to treat
distinct infection events as independent and to account for
treatment. However, the need to incorporate imperfect detection
of parasites depending on the number of co-infections complicates
the application of this model. Indeed, hosts with sub-patent
infections are a greater proportion of the infected hosts at lower
prevalence levels because a lower multiplicity of infection
translates into a lower probability that there is at least one clone
with a density above the detection level [18,19].
Seasonality and age effects also need to be considered. Malaria
transmission generally varies greatly by season, as illustrated by
our Ethiopian example, so information collected at only one time
of the year is likely to be unrepresentative, leading to biased
estimates of FOI. Case-incidence is the main driver of seasonality
in the estimates of FOI, so it is probably good enough to use
annual averages for the prevalence and treatment-seeking
behavior, but it is worrying that these data are usually collected
only at one time-point which may be unrepresentative. Addition-
ally, given the absence of diagnostics and widespread use of
ineffective anti-malarials in much of the private sector, fluctuations
in effective and appropriate treatment levels in the private sector
Table 1. Monthly malaria treatments at Bulbulla and
Asendabo health centers.
Year Month Bulbulla HC Asendabo HC
2010 Apr 139 316
May 297 288
Jun 979 398
Jul 331 222
Aug 201 195
Sep 95 166
Oct 132 333
Nov 89 135
Dec 46 102
2011 Jan 35 57
Feb 30 19
Mar 27 11
Apr 9 43
May 28 78
Jun 62 106
Jul 94 261
Aug 835 534
Sep 243 293
doi:10.1371/journal.pone.0042861.t001
Table 2. Other parameter values.
Model parameter Input Value
Daily natural clearance rate 1/200
Detectability 50%
Observed prevalence in Bulbulla 7.2%
Proportion of antimalarial drugs obtained in private sector 65.7%
Catchment population Bulbulla 54,157
Observed prevalence Asendabo 10.4%
Catchment population Asendabo 48,111
doi:10.1371/journal.pone.0042861.t002
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do not necessarily track the patterns in the public sector [31].
Moreover, MISs mainly collect data from children less than five
years of age, and both prevalence and treatment seeking behavior
can vary by age and on small spatial scales. In our data example,
we used data for two to ten year olds, a limitation of the approach,
as compared to all ages prevalence data. All this adds to the case
for MISs to be conducted in a rolling manner throughout the year
[32], to be extended to include older people, and our model to be
validated in a range of settings, including those where other
estimates of FOI are available.
Despite all these reservations, estimating the FOI from a
combination of case series and cross-sectional survey data remains
a much more practicable means of tracking malaria transmission
in programs than entomological assessment of the inoculation rate.
The FOI and the EIR are closely related but not identical, because
the FOI excludes bites by infectious mosquitoes that do not end up
being infectious to humans [5,33,34], making FOI a more
appropriate measure of transmission, while EIR is technically a
measure of exposure. FOI is only indirectly related to burden of
disease, which also depends on levels of clinical immunity, on
promptness of treatment, and on the quality of care for severe
disease. Measurement of disease burden is explored in a
companion paper [35]. As malaria control programs, even in
sub-Saharan Africa, increasingly re-orient themselves from reduc-
ing disease towards reducing transmission, there is a need for them
to clearly distinguish between measures of disease burden and
transmission, and estimating FOI may be the best avenue to
accurately understand the level of transmission achieved. This
requires comprehensive information on patient treatment rates
from all care-providers as well as prevalence data, with allowance
for imperfect detection of parasites.
Figure 4. Monthly and average force of infection estimates for Bulbulla and Asendabo health center catchment areas in Ethiopia.
Monthly (dashed lines) and annual average force of infection (l0 : new infections prior to any treatment per person month) estimates assuming
perfect detectability (black lines) or 50% detectability (red lines) in A Bulbulla and B Asendabo health center catchment areas.
doi:10.1371/journal.pone.0042861.g004
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Conclusions
A reversible catalytic model that incorporates treatment and
detectability can be used to estimate P. falciparum malaria FOI
from HMIS and prevalence data from community surveys. The
approach also requires an estimate of the proportion of effective
treatments included in the HMIS out of all treatments and uses
estimates from research studies of levels of detectability of parasites
and of duration of untreated infections. This approach is much
more straightforward than measuring the entomological inocula-
tion rate. It is mainly applicable in low transmission settings, where
there is a critical need for estimation of transmission rates when
considering re-orientation of control programs towards elimina-
tion. Accurate results depend on availability of time series of
numbers of treatments of confirmed cases from both private and
public providers and an understanding of the levels of both patent
and undetectable infections prevalent in an area.
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Box S1 Standard metrics of malaria transmission.
Adapted from Smith DL, Smith TA and Hay I; Chapter 7.
Measuring Malaria for Elimination. in A Prospectus for malaria
elimination. The Malaria Elimination Group: The Global Health
Group UCSF Global Health Sciences (2009).
(DOCX)
Box S2 Model Parameters and Inputs.
(DOCX)
Figure S1 Compartment models for effects of treatment
on prevalence. Model A corresponds to the model in the main
text, which considers all parasites in an infected host as equivalent;
Model B is an infinite server queuing model, where the effect of
treatment is to remove only one infection at a time. The value of n
is the number of concurrent co-infections (multiplicity of infection):
only the first three infected categories are shown. Model C is a
variant of the infinite server model, in which treatment removes all
infections.
(TIF)
Figure S2 Comparison of prevalence values predicted
by different models. The black dots each correspond to the
means of 1000 simulations of the model illustrated in Figure S1C.
The red lines to prevalence predicted by model S1A; the blue lines
to that predicted by model S1B, and the black lines to the
approximation in equation A11. In all cases a clearance rate of
0.005 per day was assumed.
(TIF)
File S1 Models treating super-infections as indepen-
dent of each other.
(DOCX)
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